Cargando…
Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) remains a morbid disease with poor prognosis and treatment that typically leaves patients with permanent damage to critical functions such as eating and talking. Currently only three targeted therapies are FDA approved for use in HNSCC, two of which are...
Autores principales: | Choonoo, Gabrielle, Blucher, Aurora S., Higgins, Samuel, Boardman, Mitzi, Jeng, Sophia, Zheng, Christina, Jacobs, James, Anderson, Ashley, Chamberlin, Steven, Evans, Nathaniel, Vigoda, Myles, Cordier, Benjamin, Tyner, Jeffrey W., Kulesz-Martin, Molly, McWeeney, Shannon K., Laderas, Ted |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785123/ https://www.ncbi.nlm.nih.gov/pubmed/31596908 http://dx.doi.org/10.1371/journal.pone.0223639 |
Ejemplares similares
-
Natural Product Target Network Reveals Potential for Cancer Combination Therapies
por: Chamberlin, Steven R., et al.
Publicado: (2019) -
Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib
por: Vigoda, Myles, et al.
Publicado: (2022) -
Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models
por: Ouyang, Xiaoming, et al.
Publicado: (2018) -
Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma
por: Anderson, Ashley N., et al.
Publicado: (2020) -
IL-10 and integrin signaling pathways are associated with head and neck cancer progression
por: Bornstein, Sophia, et al.
Publicado: (2016)